AGFA-GEVAERT NV |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.164 EUR | -2.51% |
|
-2.18% | -20.82% |
| Mar. 13 | Transcript : Agfa-Gevaert NV, 2023 Earnings Call, Mar 13, 2024 | |
| Mar. 13 | Agfa-Gevaert NV Reports Impairment Losses on Intangibles and Pp&E for the Fourth Quarter Ended December 31, 2023 | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The company shows low valuation levels, with an enterprise value at 0.07 times its sales.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The opinion of analysts covering the stock has improved over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -20.82% | 198M | B+ | ||
| +8.78% | 219B | B | ||
| +8.24% | 187B | B- | ||
| +11.16% | 134B | B- | ||
| +26.12% | 101B | A- | ||
| +0.30% | 62.27B | A- | ||
| +16.21% | 52.82B | B+ | ||
| -1.63% | 47.49B | B+ | ||
| -1.11% | 40.79B | A | ||
| +12.16% | 39.35B | - |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- AGFB Stock
- Ratings Agfa-Gevaert NV
